Merck KGaA said it’s seeing the beginning of a post-Covid pandemic rebound in life sciences as it reaffirmed the group’s sales and profit guidance for the full year. The German science and ...

Merck KGaA’sMRK-1.94%decrease; red down pointing triangle shares jumped after the German company said booming artificial-intelligence demand would help its electronics sales grow faster than ...

And Merck's business extends beyond this single product. The company recently earned approval for Winrevair, a therapy for pulmonary arterial hypertension with a new mechanism of action.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Merck (NYSE:MRK) also announced interim data from a Phase 3 trial testing clesrovimab against RSV therapy palivizumab in infants and children at a higher risk for severe RSV disease. As for the ...

KeyVibe-010, a randomized Phase 3 trial, was testing the investigational coformulation of vibostolimab, an anti-TIGIT antibody, and Merck’s blockbuster anti-PD-1 therapy, pembrolizumab (Keytruda ...

Oct 23 (Reuters) - Merck (MRK.N), opens new tab has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the privately held biotech firm ...

Are you a print subscriber? Activate your account. By Garett Sloane - 2 hours 35 min ago By Gillian Follett - 2 hours 35 min ago By E.J. Schultz - 2 hours 35 min ago By Jack Neff - 2 hours 35 min ...

FILE- This May 1, 2018, file photo shows Merck corporate headquarters in Kenilworth, N.J. RAHWAY, N.J. – While the Dow Jones Industrial Average has reached all-time highs recently, one of its ...

The information provided here does not include promotional content or endorsements of the therapy's effectiveness, as its success will depend on the outcomes of the ongoing trial. Merck and ...

Three months after revealing that its respiratory syncytial virus (RSV) preventive antibody clesrovimab had passed muster in a phase 2b/3 trial, Merck is putting numbers to the claim. Clesrovimab ...

(Reuters) - Merck has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the privately held biotech firm said on Wednesday. As part of ...